Hemab Therapeutics HoldingsCOAG
Recorded

Hemab Therapeutics Holdings Jefferies Global Healthcare Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration28 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Maury RaycroftBiotech Analyst

All set? Ready? Yes. Hi, everyone.

Maury RaycroftBiotech Analyst

My name is Maury Raycroft, and one of the biotech analysts at Jefferies. I'd like to welcome the CEO of Hemab, Benny Sørensen. Thanks so much for joining us today, Benny.

Benny SørensenCEO

Thank you for having us.

Maury RaycroftBiotech Analyst

We are going to do a fireside chat format. For those who are new to the story, if you can give a brief intro to COAG.

Benny SørensenCEO

Sure. Hemab Therapeutics is a biotech company where we are pursuing a vision of reimagining treatment of blood coagulation disorders. It is a biotech company exclusively focused in coagulation, hence the COAG ticker. We are proud of the progress we have made. We have a molecule, sutacimig, that is now in phase III pivotal trials in Glanzmann thrombasthenia. Same molecule is being prosecuted in a second indication called Factor VII deficiency, where we have phase II data coming soon. I am sure we will chat about that. Then the second asset, HMB-002, is a molecule for prophylaxis for von Willebrand disease. Then our latest, HMB-003, is for heavy menstrual bleeding.

Maury RaycroftBiotech Analyst

Yep. Yeah, it is a great intro. Maybe let us start off with sutacimig for Glanzmann. You just announced the start of your phase III study. We saw the trials posted on ClinicalTrials.gov a couple of days ago. FDA recommended considering a randomized controlled study while acknowledging the feasibility challenges in Glanzmann. Can you provide more color on the feedback and whether any specifics related to how the single-arm study should be run were discussed?

Benny SørensenCEO

Sure. We have had really constructive dialogue with the regulatory authorities here, and discussed what would be the best way to kind of advance sutacimig as a first-ever prophylactic treatment for Glanzmann. I think it is not unusual that regulators would kind of like, "Have you considered a randomized trial versus a single-arm trial?" The dialogue has been very constructive. It is very clear based on the phase II data we have, that we need to somewhat control a substantial amount of variability. The strongest way of doing that is a single-arm trial. It will enable us to do a 90% power for a minimum 50% effect. We think that is super important to kind of minimize the technical risk to really give the largest possible hope for these patients in having a first-ever prophylactic treatment.

Maury RaycroftBiotech Analyst

Yeah. Makes sense. As far as the endpoints go and everything, you are not compromising anything there?

Benny SørensenCEO

No, we are fully aligned on the primary endpoint being the annualized treated bleed rate. We have collaborated really closely with the agency, building a really state-of-the-art electronic validated bleed diary that gives us an opportunity to collect this data with really high quality. So, primary endpoint, all secondary endpoint fully endorsed with the regulators. Our approach to analyzing the data, long time ago we agreed on the dose, the dose regime. Hey, there's a lot more that we agree on than we are still discussing.

Maury RaycroftBiotech Analyst

Makes sense. As you get the phase III started in the U.S., maybe talk about the status ex-U.S., and it's an ultra-rare disease. How many sites do you need for this study? You're going to have 75 patients.

Benny SørensenCEO

Yeah. So it's approximately 75 patients. We've spent almost a half a year building a really deep understanding of feasibility. We have identified multiple more patients than the 75 that we need to enroll. You can expect this to be enrolled in multiple countries and multiple sites, more sites than we probably have patients need for. That's the best practices when it comes to executing in rare disease. Right now, we are open in the U.S. as well as two non-U.S. regions as well. First half of next year, we'll provide a little bit more metrics on enrollment and timelines, so that you guys can start putting a dot in the ground on when the data comes.

Maury RaycroftBiotech Analyst

Okay. Yeah, that's helpful. I think we're estimating you could potentially get the data in like second half of 2028. Do you think that's a reasonable timeframe or?

Benny SørensenCEO

I usually kind of remind you of the two times three by 2030.

Benny SørensenCEO

Yeah. There will be two commercial programs in 2030.

Benny SørensenCEO

Sooner is better. Right. Two late-stage programs, two early-stage programs.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day